The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Valiant Laboratories's Revenue for the
three
months ended in Mar. 2026 was ₹920 Mil. Valiant Laboratories's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₹936 Mil.
Hence, Valiant Laboratories's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.98.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Valiant Laboratories Receivables Turnover Related Terms
Valiant Laboratories Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VALIANTLAB vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a Receivables Turnover of 0.98 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Valiant Laboratories and its competitors. According to the industry distribution chart, Valiant Laboratories ranks #753 out of 946 companies in the Drug Manufacturers industry, placing it in the top 79.6%.
Is Valiant Laboratories' Receivables Turnover too high?
Valiant Laboratories' current Receivables Turnover is 0.98. The Drug Manufacturers industry median Receivables Turnover is 5.07. Valiant Laboratories' value of 0.98 is 80.7% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #753 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Valiant Laboratories has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #753 out of 946 companies for Receivables Turnover. This places Valiant Laboratories in the lower half of its industry. The industry median Receivables Turnover is 5.07. Valiant Laboratories' value of 0.98 is 80.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Receivables Turnover of 0.98 is 80.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Receivables Turnover is 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹102.61, compared to a current price of ₹65.51 — trading 36.2% below its estimated fair value. The current Receivables Turnover is 0.98 and 80.7% below the Drug Manufacturers industry median of 5.07. Valiant Laboratories' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Receivables Turnover is 0.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹65.51 is trading 36.2% below its estimated GF Value™ of ₹102.61.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Receivables Turnover: 0.98
GF Value™: ₹102.61 vs. price of ₹65.51 (36.2% below fair value)
Industry Position: 80.7% below the Drug Manufacturers median (#753 of 946)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
58GF Score
Get the complete analysis for NSE:VALIANTLAB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
